ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

PROVEN BLEED PROTECTION IN A COUNTRY-WIDE SWITCH⁷

In a four-year retrospective study (two years pre-switch and two years
post-switch), all patients with haemophilia B in Ireland (N=28) were
switched from SHL FIX* to ALPROLIX prophylaxis, reporting:⁷

Improved ABRs⁷

ABRs improved with ALPROLIX vs pre-switch FIX⁷

Pre- and post-switch median ABR (N=28)^†7

More patients with zero bleeds⁷

14%

numerical increase in patients
experiencing zero bleeds

12–24 months after switching from SHL FIX 18% (5/28) vs. 4% (1/28)⁷

p-values not reported

Reduced factor consumption⁷

28% reduction in weekly (median) factor consumption with ALPROLIX⁷

Pre- and post-switch factor consumption (N=21)⁷

Reduced injection frequency⁷

Most patients halved the number of injections
per year with ALPROLIX

52 vs 104 injections^¶7

*Includes patients previously treated with on-demand (n=6) and prophylactic SHL FIX (n=22) at the point of switchover.^{7 †}0–12 months after initiation of ALPROLIX prophylaxis.^{7 ‡}Median change between pre- and post-switch ABR.^{7 §}Median change between pre- and post-switch factor consumption.^{7 ¶}Calculated from dosing schedules pre- and post-switch. Most patients on prophylaxis with SHL FIX were on twice-weekly injections (n=19/22).⁷
ABR, annualised bleeding rate; FIX, factor IX; IU, international unit; SHL, standard half-life.

Retrospective real-world comparison after country-wide switch from SHL FIX to ALPROLIX in Ireland⁷

*As part of a national tender process.^{7 †}Two patients were treated episodically and with prophylaxis for differing time periods in the two years prior to switchover.⁷
FIX, factor IX; SHL, standard half-life.

No safety data were collected.